

BIBLIOGRAPHY

- Adhikari, B., Awab, G. R., & von Seidlein, L. (2021). Rolling out the radical cure for vivax malaria in Asia: a qualitative study among policy makers and stakeholders. *Malar J*, 20(1), 164. doi:10.1186/s12936-021-03702-5
- Almeida, E. D., & Vieira, J. L. (2016). Factors associated with non-adherence to the treatment of vivax malaria in a rural community from the Brazilian Amazon Basin. *Rev Soc Bras Med Trop*, 49(2), 248-251. doi:10.1590/0037-8682-0275-2015
- Aung, P. L., Soe, M. T., Soe, T. N., Oo, T. L., Win, K. M., Cui, L., . . . Parker, D. M. (2023). Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019-2020. *Sci Rep*, 13(1), 5963. doi:10.1038/s41598-023-32371-4
- Chen, N., Auliff, A., Rieckmann, K., Gatton, M., & Cheng, Q. (2007). Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. *J Infect Dis*, 195(7), 934-941. doi:10.1086/512242
- Chu, C. S., Bancone, G., Nosten, F., White, N. J., & Luzzatto, L. (2018). Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. *Malaria journal*, 17(1), 101. doi:10.1186/s12936-018-2248-y
- Chu, C. S., Phyo, A. P., Turner, C., Win, H. H., Poe, N. P., Yotyingaphiram, W., . . . White, N. J. (2019). Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. *Clin Infect Dis*, 68(8), 1311-1319. doi:10.1093/cid/ciy735
- Department of Public Health. (2020). Ministry of Health, Myanmar, . Retrieved from <http://www.doph.gov.mm/>
- Department of Public Health, M. o. H. a. S. (2016) *National strategic plan: intensifying malaria control and accelerating progress towards malaria elimination (2016–2020)*. DoPH, MOHS; 2016.
- Department of Public Health, M. o. H. a. S. (2019). National Malaria Treatment Guidelines for ICMV. Retrieved from <http://malariamatters.org/wp-content/uploads/2019/11/1Mya-2.jpg>

- Deressa, A., Eyeberu, A., Gamachu, M., Debella, A., & Abamecha Ababulgu, F. (2022). Perceived performances of peer learning and education approach on malaria prevention through primary schools communities in rural Ethiopia: Peer educators' perspectives. *Front Public Health*, 10, 861253. doi:10.3389/fpubh.2022.861253
- Dinelly, K. M. O., Vitor-Silva, S., Brito-Sousa, J. D., Sampaio, V. S., Silva, M. G. O., Siqueira, A. M., . . . Melo, G. C. (2021). Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria. *Malar J*, 20(1), 266. doi:10.1186/s12936-021-03793-0
- Douglas, N. M., Poespoprodjo, J. R., Patriani, D., Malloy, M. J., Kenangalem, E., Sugiarto, P., . . . Price, R. N. (2017). Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. *PLoS Med*, 14(8), e1002379. doi:10.1371/journal.pmed.1002379
- Flatie, B. T., & Munshea, A. (2021). Knowledge, Attitude, and Practice towards Malaria among People Attending Mekaneeyesus Primary Hospital, South Gondar, Northwestern Ethiopia: A Cross-Sectional Study. *J Parasitol Res*, 2021, 5580715. doi:10.1155/2021/5580715
- Gellad, W. F., Grenard, J., & McGlynn, E. A. (2009). *A Review of Barriers to Medication Adherence: A Framework for Driving Policy Options*. Santa Monica, CA: RAND Corporation.
- Han, K. T., Wai, K. T., Oo, T., Thi, A., Han, Z., Aye, D. K. H., . . . Prachumsri, J. (2018). Access to primaquine in the last mile: challenges at the service delivery points in pre-elimination era, Myanmar. *Tropical medicine and health*, 46, 32-32. doi:10.1186/s41182-018-0115-8
- Imwong, M., Snounou, G., Pukrittayakamee, S., Tanomsing, N., Kim, J. R., Nandy, A., . . . White, N. J. (2007). Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. *J Infect Dis*, 195(7), 927-933. doi:10.1086/512241
- Jimmy, B., & Jose, J. (2011). Patient medication adherence: measures in daily practice. *Oman Med J*, 26(3), 155-159. doi:10.5001/omj.2011.38

Kathirvel, S., Tripathy, J. P., Tun, Z. M., Patro, B. K., Singh, T., Bhalla, A., . . . Wilkinson, E. (2017). Physicians' compliance with the National Drug Policy on Malaria in a tertiary teaching hospital, India, from 2010 to 2015: a mixed method study. *Trans R Soc Trop Med Hyg*, 111(2), 62-70. doi:10.1093/trstmh/trx020

Kebede, Y., Abebe, L., Alemayehu, G., Sudhakar, M., & Birhanu, Z. (2020). Effectiveness of peer-learning assisted primary school students educating the rural community on insecticide-treated nets utilization in Jimma-zone Ethiopia. *Malar J*, 19(1), 331. doi:10.1186/s12936-020-03401-7

Khantikul, N., Butraporn, P., Kim, H. S., Leemingsawat, S., Tempongko, M. A., & Suwonkerd, W. (2009). Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand. *J Health Popul Nutr*, 27(1), 4-13. doi:10.3329/jhpn.v27i1.3313

Krotoski, W. A., Garnham, P. C., Bray, R. S., Krotoski, D. M., Killick-Kendrick, R., Draper, C. C., . . . Guy, M. W. (1982). Observations on early and late post-sporozoite tissue stages in primate malaria. I. Discovery of a new latent form of Plasmodium cynomolgi (the hypnozoite), and failure to detect hepatic forms within the first 24 hours after infection. *Am J Trop Med Hyg*, 31(1), 24-35.

Lacerda, M. V. G., Llanos-Cuentas, A., Krudsood, S., Lon, C., Saunders, D. L., Mohammed, R., . . . Koh, G. (2019). Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. *N Engl J Med*, 380(3), 215-228. doi:10.1056/NEJMoa1710775

Llanos-Cuentas, A., Lacerda, M. V. G., Hien, T. T., Vélez, I. D., Namaik-Larp, C., Chu, C. S., . . . Green, J. A. (2019). Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. *N Engl J Med*, 380(3), 229-241. doi:10.1056/NEJMoa1802537

Macías Saint-Gerons, D., Rodovalho, S., Barros Dias Á, L., Lacerda Ulysses de Carvalho, A., Beratarrechea, A., Monteiro, W. M., . . . Castro, J. L. (2022). Strengthening therapeutic adherence and pharmacovigilance to antimalarial treatment in Manaus, Brazil: a multicomponent strategy using mHealth. *Malar J*, 21(1), 28. doi:10.1186/s12936-022-04047-3

Maneeboonyang, W., Lawpool Sri, S., Puangsa-Art, S., Yimsamran, S., Thanyavanich, N., Wuthisen, P., . . . Singhasivanon, P. (2011). Directly observed therapy with primaquine to

reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border.

Southeast Asian J Trop Med Public Health, 42(1), 9-18.

Markus, M. B. (2019). Killing of Plasmodium vivax by Primaquine and Tafenoquine. *Trends in Parasitology*, 35(11), 857-859. doi:<https://doi.org/10.1016/j.pt.2019.08.009>

Nguyen, T. T., Nguyen, X. X., Ronse, M., Nguyen, Q. T., Ho, P. Q., Tran, D. T., . . . Gryseels, C. (2020). Diagnostic Practices and Treatment for P. vivax in the InterEthnic Therapeutic Encounter of South-Central Vietnam: A Mixed-Methods Study. *Pathogens*, 10(1). doi:10.3390/pathogens10010026

Organization, W. H. (2015). *Guidelines for the treatment of malaria*: World Health Organization.

Poespoprodjo, J. R., Burdam, F. H., Candrawati, F., Ley, B., Meagher, N., Kenangalem, E., . . . Price, R. N. (2022). Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. *Lancet Infect Dis*, 22(3), 367-376. doi:10.1016/s1473-3099(21)00358-3

Pourhoseingholi, M. A., Vahedi, M., & Rahimzadeh, M. (2013). Sample size calculation in medical studies. *Gastroenterol Hepatol Bed Bench*, 6(1), 14-17.

Rahi, M., Sirohi, P. R., & Sharma, A. (2023). Supervised administration of primaquine may enhance adherence to radical cure for P. vivax malaria in India. *Lancet Reg Health Southeast Asia*, 13, 100199. doi:10.1016/j.lansea.2023.100199

Rahmalia, A., Poespoprodjo, J. R., Landuwulang, C. U. R., Ronse, M., Kenangalem, E., Burdam, F. H., . . . Gryseels, C. (2023). Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-methods study. *Malar J*, 22(1), 162. doi:10.1186/s12936-023-04578-3

Rishikesh, K., & Saravu, K. (2016). Primaquine treatment and relapse in Plasmodium vivax malaria. *Pathog Glob Health*, 110(1), 1-8. doi:10.1080/20477724.2015.1133033

Rueangweerayut, R., Bancone, G., Harrell, E. J., Beelen, A. P., Kongpatanakul, S., Möhrle, J. J., . . . Green, J. A. (2017). Hemolytic Potential of Tafenoquine in Female Volunteers

Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers. *Am J Trop Med Hyg*, 97(3), 702-711. doi:10.4269/ajtmh.16-0779

Saita, S., Roobsoong, W., Khammaneechan, P., Sukchan, P., Lawpoolsri, S., Sattabongkot, J., . . . Parker, D. M. (2023). Community acceptability, participation, and adherence to mass drug administration with primaquine for Plasmodium vivax elimination in Southern Thailand: a mixed methods approach. *Malar J*, 22(1), 17. doi:10.1186/s12936-023-04443-3

Takeuchi, R., Lawpoolsri, S., Imwong, M., Kobayashi, J., Kaewkungwal, J., Pukrittayakamee, S., . . . Singhasivanon, P. (2010). Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. *Malar J*, 9, 308. doi:10.1186/1475-2875-9-308

Taylor, A. R., Watson, J. A., Chu, C. S., Puaprasert, K., Duanguppama, J., Day, N. P. J., . . . White, N. J. (2019). Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. *Nat Commun*, 10(1), 5595. doi:10.1038/s41467-019-13412-x

Valdes, A., Epelboin, L., Mosnier, E., Walter, G., Vesin, G., Abboud, P., . . . Djossou, F. (2018). Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison. *Malar J*, 17(1), 237. doi:10.1186/s12936-018-2378-2

Wångdahl, A., Sondén, K., Wyss, K., Stenström, C., Björklund, D., Zhang, J., . . . Färnert, A. (2022). Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. *Clin Infect Dis*, 74(7), 1199-1207. doi:10.1093/cid/ciab610

Win Han, O., Gold, L., Moore, K., Agius, P. A., & Fowkes, F. J. I. (2019). The impact of community-delivered models of malaria control and elimination: a systematic review. *Malar J*, 18(1), 269. doi:10.1186/s12936-019-2900-1

World Health Organization. (2003). Adherence to long-term therapies : evidence for action. In. Geneva: World Health Organization.

World Health Organization. (2015). *Control and elimination of plasmodium vivax malaria: a technical brief*. Geneva: World Health Organization.

World Health Organization. (2019). New opportunities to prevent Plasmodium vivax malaria relapse. Retrieved from <https://www.who.int/news/item/25-02-2019-new-opportunities-to-prevent-p-vivax-malaria-relapse#:~:text=vivax%20malaria%2C%20WHO%20recommends%20standard,a%20full%202%2Dweek%20period.>

World Health Organization. (2021). World Malaria Report 2021. Retrieved from <https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021>

World Health Organization. (2022). *World malaria report 2022*: World Health Organization.

Xu, Y., Dong, Y., Deng, Y., Huang, H., Chen, M., Liu, Y., . . . Zheng, W. (2023). Molecular identification of vivax malaria relapse patients in the Yunnan Province based on homology analysis of the Plasmodium vivax circumsporozoite protein gene. *Parasitol Res*, 122(1), 85-96. doi:10.1007/s00436-022-07700-7

Yoshii, A., Sekihara, M., Furusawa, T., Hombhanje, F., & Tsukahara, T. (2019). Factors associated with children's health facility visits for primaquine treatment in rural Papua New Guinea. *Malar J*, 18(1), 42. doi:10.1186/s12936-019-2675-4

Zeng, W., Liu, N., Li, Y., Gao, A., Yuan, M., Ma, R., . . . Feng, X. (2022). Prevalence of glucose-6-phosphate dehydrogenase deficiency (G6PDd) and clinical implication for safe use of primaquine in malaria-endemic areas of Hainan Province, China. *Front Public Health*, 10, 1010172. doi:10.3389/fpubh.2022.1010172